Jan 23, 2023 | Past Events
Philogen announces its attendance at the European Bispecific and Multispecific Antibody congress in Amsterdam. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 23rd of February 2023 entitled “Engineering Antibody-Cytokine...Jan 23, 2023 | Past Events
Philogen announces its attendance at the Annual Next-Gen Immuno-Oncology Conference congress in London. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 9th of March 2023 entitled “Engineering Antibody-Cytokine Fusion...Dec 7, 2022 | Past Events
Philogen announces its attendance at JP Morgan 2023. Prof. Dr. Dario Neri, CEO and CSO of Philogen, and Dr. Emanuele Puca, Investor Relations and Business Development, will be available for meeting to explore novel collaboration opportunities.Dec 7, 2022 | Past Events
Philogen announces its attendance at the 5th MidCap Conference organised by Mediobanca. Prof. Dario Neri (CEO and CSO), Laura Baldi (CFO), and Emanuele Puca (Investor Relations) will participate at the event. The objective of the MidCap Conference is to bring the...Dec 7, 2022 | Past Events
Philogen announces its attendance at World ADC2023 in London. Dr. Samuele Cazzamalli (Head of Small Molecule Therapeutics at Philochem) is giving a lecture on the 14th of March 2023 entitled “Enhancing the Therapeutic Index of ADCs to Penetrate Solid Tumours:...Dec 3, 2022 | 2022, Past Events
Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs): A Comparative Evaluation” Please...
Recent Comments